The stock of Gyre Therapeutics Inc (GYRE) has seen a -24.49% decrease in the past week, with a -28.46% drop in the past month, and a -12.37% decrease in the past quarter. The volatility ratio for the week is 11.76%, and the volatility levels for the past 30 days are at 10.00% for GYRE. The simple moving average for the past 20 days is -23.95% for GYRE’s stock, with a -29.90% simple moving average for the past 200 days.
Is It Worth Investing in Gyre Therapeutics Inc (NASDAQ: GYRE) Right Now?
GYRE has 36-month beta value of 1.79. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GYRE is 16.16M, and currently, short sellers hold a 8.33% ratio of that float. The average trading volume of GYRE on March 19, 2025 was 91.57K shares.
GYRE) stock’s latest price update
The stock price of Gyre Therapeutics Inc (NASDAQ: GYRE) has plunged by -30.21 when compared to previous closing price of 12.28, but the company has seen a -24.49% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-17 that Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025 Commercial launch in the PRC of generic nintedanib for the treatment of IPF and avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia expected in 2025 Initiation of U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis expected in 2025 Full year 2025 total revenue guidance of $118 to $128 million SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. “2025 is shaping up to be a pivotal year for Gyre across both our commercial-stage and clinical-stage portfolios.
Analysts’ Opinion of GYRE
Stephens, on the other hand, stated in their research note that they expect to see GYRE reach a price target of $19, previously predicting the price at $18. The rating they have provided for GYRE stocks is “Overweight” according to the report published on April 29th, 2021.
Piper Sandler gave a rating of “Overweight” to GYRE, setting the target price at $15 in the report published on February 10th of the previous year.
GYRE Trading at -23.81% from the 50-Day Moving Average
After a stumble in the market that brought GYRE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.89% of loss for the given period.
Volatility was left at 10.00%, however, over the last 30 days, the volatility rate increased by 11.76%, as shares sank -32.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.58% lower at present.
During the last 5 trading sessions, GYRE fell by -24.49%, which changed the moving average for the period of 200-days by -13.87% in comparison to the 20-day moving average, which settled at $11.27. In addition, Gyre Therapeutics Inc saw -29.17% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GYRE starting from Ma Songjiang, who sale 2,000 shares at the price of $12.31 back on Mar 14 ’25. After this action, Ma Songjiang now owns 2,831,260 shares of Gyre Therapeutics Inc, valued at $24,620 using the latest closing price.
Ma Songjiang, the President of Gyre Therapeutics Inc, sale 2,000 shares at $11.80 during a trade that took place back on Mar 13 ’25, which means that Ma Songjiang is holding 2,833,260 shares at $23,600 based on the most recent closing price.
Stock Fundamentals for GYRE
Current profitability levels for the company are sitting at:
- 0.15 for the present operating margin
- 0.96 for the gross margin
The net margin for Gyre Therapeutics Inc stands at 0.27. The total capital return value is set at 0.15.
Based on Gyre Therapeutics Inc (GYRE), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -2.28. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 46.18.
Currently, EBITDA for the company is 16.16 million with net debt to EBITDA at -0.59. When we switch over and look at the enterprise to sales, we see a ratio of 6.86. The receivables turnover for the company is 3.63for trailing twelve months and the total asset turnover is 0.84. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.72.
Conclusion
To put it simply, Gyre Therapeutics Inc (GYRE) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
